Vergne P, Bertin P, Bonnet C, Scotto C, Trèves R
Department of Rheumatology, CHU Dupuytren, Limoges, France.
Drug Saf. 2000 Oct;23(4):279-93. doi: 10.2165/00002018-200023040-00002.
The purpose of this article is to review the causes, the clinical manifestations and the management of the more frequent drug-induced rheumatic disorders. These include: (i) articular and periarticular manifestations induced by fluoroquinolones, nonsteroidal anti-inflammatory drugs, injections of corticosteroids, and retinoids; (ii) multisystemic manifestations such as drug-induced lupus and arthritis induced by vaccination, Bacillus Calmette-Guerin therapy and cytokines; (iii) drug-induced disorders of bone metabolism (corticosteroid-induced osteoporosis, drug-induced osteomalacia and osteonecrosis); and (iv) iatrogenic complex regional pain syndromes. Disorders caused by nonpharmacological and rarely used treatments have been deliberately excluded. Knowledge of these drug-induced clinical symptoms or syndromes allows an earlier diagnosis and treatment, and earlier drug withdrawal if necessary. With the introduction of new medications such as the recombinant cytokines and antiretroviral treatments, the number of drug-induced rheumatic disorders is likely to increase.
本文旨在综述较常见的药物性风湿性疾病的病因、临床表现及治疗。这些疾病包括：（i）由氟喹诺酮类、非甾体抗炎药、皮质类固醇注射剂及维甲酸引起的关节及关节周围表现；（ii）多系统表现，如药物性狼疮以及由疫苗接种、卡介苗治疗和细胞因子引起的关节炎；（iii）药物性骨代谢紊乱（皮质类固醇诱导的骨质疏松症、药物性骨软化症和骨坏死）；以及（iv）医源性复杂性区域疼痛综合征。由非药物及极少使用的治疗方法引起的疾病已被特意排除。了解这些药物性临床症状或综合征有助于早期诊断和治疗，必要时可尽早停药。随着重组细胞因子和抗逆转录病毒治疗等新药的引入，药物性风湿性疾病的数量可能会增加。
